IDH1 and IDH2 mutants identified in cancer lose inhibition by isocitrate because of a change in their binding sites
Juan Pablo Bascur, Melissa Alegría‐Arcos, Ingrid Araya‐Durán, Ezequiel Juritz, Fernando Danilo González-Nilo, Daniel Eduardo Almonacid
This paper identifies how IDH1 and IDH2 mutations lose inhibition by isocitrate due to changes in their binding sites, using molecular docking and binding site analysis.
bioRxiv · May 2, 2019 · PreprintBioinformatics